P370: Maintenance of health-related quality of life improvements with upadacitinib treatment among patients with moderately to severely active ulcerative colitis: results from 52-week phase 3 study U ACHIEVE maintenanceECCO'22Year: 2022
Authors: Panés, J.(1);Loftus, E.V.J.(2);Higgins, P.(3);Lindsay, J.O.(4);Zhou, W.(5);Yao, X.(5);Ilo, D.(5);Phillips, C.(5);Tran, J.(5);Sanchez Gonzalez, Y.(5);Vermeire, S.(6);
(1)Hospital Clinic Barcelona- IDIPABS- CIBERehd- Barcelona- Spain, n/a, Barcelona, Spain;(2)Mayo Clinic College of Medicine, n/a, Rochester, United States;(3)University of Michigan, n/a, Ann Arbor, United States;(4)The Royal London Hospital- Barts Health NHS Trust, Department of Gastroenterology, London, United Kingdom;(5)AbbVie Inc., n/a, North Chicago, United States;(6)University Hospital Leuven, n/a, Leuven, Belgium;
P371: The addition of intravenous, high dose, bolus of methyl-prednisolone increases the early clinical response to oral corticosteroids in moderately active ulcerative colitis. Preliminary results of a prospective, controlled, multicentre, randomised, open-label study.ECCO'22Year: 2022
Authors: Domènech MoralPhD, E.(1);Llaó, J.(2);Mañosa, M.(1);Martín-Arranz, E.(3);Zabana, Y.(4);Navarro-Llavat, M.(5);Garcia-Planella, E.(6);Busquets, D.(7);Pineda, J.R.(8);Monfort, D.(9);Gutiérrez, A.(10);García-Alonso, F.J.(11);Menchén, L.A.(12);Villoria, A.(13);
(1)Germans Trias i Pujol University Hospital and CIBEREHD, Gastroenterology, Badalona, Spain;(2)Althaia Xarxa Assistencial Universitària de Manresa, Gastroenterology, Manresa, Spain;(3)Hospital Universitario La Paz, Gastroenterology, Madrid, Spain;(4)Hospital Universitari Mútua Terrassa and CIBEREHD, Gastroenterology, Terrassa, Spain;(5)Hospital de Sant Joan Despí Moisès Broggi, Gastroenterology, Sant Joan Despí, Spain;(6)Hospital de la santa Creu i Sant Pau, Gastroenterology, Barcelone, Spain;(7)Hospital Universitari Dr. Josep Trueta, Gastroenterology, Girona, Spain;(8)Xerencia Xestión Integrada de Vigo, Gastroenterology, Vigo, Spain;(9)Consorci Sanitari de Terrassa, Gastroenterology, Terrassa, Spain;(10)Hospital General Universitario de Alicante-Instituto de Investigación Sanitaria y Biomédica de Alicante ISABIAL and CIBEREHD, Gastroenterology, Alicante, Spain;(11)Hospital Universitario Río Hortega, Gastroenterology, Valladolid, Samoa;(12)Hospital General Universitario/Instituto de Investigación Gregorio Marañón and CIBEREHD, Gastroenterology, Madrid, Spain;(13)Hospital Parc Taulí and CIBEREHD, Gastroenterology, Sabadell, Spain;on behalf of the CECUM study by GETECCU
P372: Accelerated dosing schedule with ustekinumab in anti-TNF refractory Crohn`s diseaseECCO'22Year: 2022
Authors: Aleman Gonzalez, H.(1);Stamp, K.(1);Whitehead, E.(1);Pattinson, A.(1);Turnbull, J.(1);Myers, S.(1);Talbot, A.(1);Sebastian, S.(1);
(1)Hull University Teaching Hospitals, Inflammatory Bowel Disease, Kingston Upon Hull, United Kingdom;
P373: Real world evidence of tofacinitib in ulcerative colitis: short and long-term effectiveness, impact of extraintestinal manifestations and immunomediated diseases and safetyECCO'22Year: 2022
Authors: Chaparro, M.(1);Acosta, D.(1);Rodríguez, C.(2);Vicuña, M.(2);Mesonero, F.(3);Barreiro-de Acosta, M.(4);Fernández-Clotet, A.(5);Hernández Martínez, Á.(6); Arroyo, M.T.(7);Vera Mendoza, I.(8);Sicilia, B.(9);Muñoz Villafranca, C.(10);Castro-Poceiro, J.(11);Martínez Cadilla, J.(12);Vázquez Morón, J.M.(13);Montil, E.(14);Sierra-Ausín , M.(15);Calafat, M.(16); Leo Carnerero, E.(17);Manceñido Marcos, N.(18);Torrealba M, L.(19); Alonso-Galán, H.(20); Benítez, J.M.(21);Ber Nieto, Y.(22);Cabello Tapia, M.J.(23);Diz-Lois Palomares, M.T.(24);García, M.J.(25);Armesto González, E.M.(26);Calvet Calvo, X.(27);Piqueras, M.(28);Dueñas Sadornil, C.(29); Pérez Calle, J.L.(30);Botella, B.(31); Martínez-Pérez, T.D.J.(32);Ramos, L.(33);Rodríguez-Grau, M.C.(34);Fernández Forcelledo, J.L.(35); Gutiérrez, A.(36);Sesé Abizanda, E.(37);Gisbert, J.P.(1);
(1)Hospital Universitario de La Princesa- Instituto de Investigación Sanitaria Princesa IIS-IP and Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas CIBEREHD, Gastroenterology Unit, Madrid, Spain;(2)Hospital Universitario de Navarra HUN and Instituto de Investigación Sanitaria de Navarra IdiSNA, Gastroenterology Unit, Pamplona, Spain;(3)Hospital Universitario Ramón y Cajal, Gastroenterology Unit, Madrid, Spain;(4)Hospital Clínico Universitario de Santiago de Compostela, Gastroenterology Unit, Santiago de Compostela, Spain;(5)Hospital Clinic of Barcelona- Institut d'Investigacions Biomèdiques August Pi i Sunyer IDIBAPS and CIBERehd, Gastroenterology Unit, Barcelona, Spain;(6)Hospital Universitario Torrecárdenas, Gastroenterology Unit, Almería, Spain;(7)Hospital Clínico Universitario Lozano Blesa and Fundación del Instituto de Investigación Sanitaria de Aragón IIS Aragón and CIBEREHD, Gastroenterology Unit, Zaragoza, Spain;(8)Hospital Universitario Puerta de Hierro Majadahonda, Gastroenterology Unit, Madrid, Spain;(9)Hospital Universitario de Burgos, Gastroenterology Unit, Burgos, Spain;(10)Hospital de Basurto, Gastroenterology Unit, Basurto, Spain;(11)Hospital Sant Joan Despí-Moisès Broggi, Gastroenterology Unit, Barcelona, Spain;(12)Hospital Álvaro Cunqueiro. Xerencia Xestión Integrada de Vigo- SERGAS. Grupo de Investigación en Patología Digestiva. Instituto de Investigación Sanitaria Galicia Sur IIS Galicia Sur. SERGAS-UVIGO, Gastroenterology Unit, Vigo, Spain;(13)Hospital Universitario Juan Ramón Jiménez, Gastroenterology Unit, Huelva, Spain;(14)Hospital Universitario Miguel Servet, Gastroenterology Unit, Zaragoza, Spain;(15)Complejo Asistencial Universitario de León, Gastroenterology Unit, León, Spain;(16)Hospital Universitari Germans Trias i Pujol and CIBEREHD, Gastroenterology Unit, Badalona, Spain;(17)Hospital Universitario Virgen del Rocío, Gastroenterology Unit, Sevilla, Spain;(18)Hospital Universitario Infanta Sofía, Gastroenterology Unit, Madrid, Spain;(19)Hospital Universitario Dr. Josep Trueta, Gastroenterology Unit, Girona, Spain;(20)Hospital Universitario Donostia- Instituto Biodonostia, Gastroenterology Unit, San Sebastián, Spain;(21)Hospital Universitario Reina Sofía and IMIBIC, Gastroenterology Unit, Córdoba, Spain;(22)Hospital San Jorge, Gastroenterology Unit, Huesca, Spain;(23)Hospital Universitario Virgen de las Nieves, Gastroenterology Unit, Granada, Spain;(24)Complejo Hospitalario Universitario A Coruña, Gastroenterology Unit, A Coruña, Spain;(25)Hospital Universitario de Valdecilla and Instituto de Investigación Sanitaria Valdecilla IDIVAL, Gastroenterology Unit, Santander, Spain;(26)Hospital San Agustín, Gastroenterology Unit, Avilés, Spain;(27)Hospital Universitari Parc Taulí- Universitat Autònoma de Barcelona and CIBERehd, Gastroenterology Unit, Sabadell, Spain;(28)Consorci Sanitari de Terrassa, Gastroenterology Unit, Barcelona, Spain;(29)Hospital Universitario de Cáceres, Gastroenterology Unit, Cáceres, Spain;(30)Hospital Universitario Fundación Alcorcón, Gastroenterology Unit, Alcorcón, Spain;(31)Hospital Universitario Infanta Cristina, Gastroenterology Unit, Madrid, Spain;(32)Hospital Virgen de la Luz, Gastroenterology Unit, Cuenca, Spain;(33)Hospital Universitario de Canarias, Gastroenterology Unit, Santa Cruz de Tenerife, Spain;(34)Hospital Universitario del Henares, Gastroenterology Unit, Madrid, Spain;(35)Hospital Sierrallana, Gastroenterology Unit, Torrelavega, Spain;(36)Hospital General Universitario de Alicante- CIBERehd and Instituto de Investigación Sanitaria y Biomédica de Alicante ISABIAL, Gastroenterology Unit, Alicante, Spain;(37)Hospital Universitario Arnau de Vilanova, Gastroenterology Unit, Lleida, Spain;on behalf of To-ReWard study group
P374: Front loading infliximab dosing regimen improves outcomes in Crohn’s Disease perianal fistulasECCO'22Year: 2022
Authors: Lloyd, A.(1);Wilkinson, A.(2);Aleman Gonzalez, H.(2);Ramachandran, S.(2);Whitehead, E.(2);Pattinson, A.(2);Stamp, K.(2);Turnbull, J.(2);Talbot, A.(2);Sebastian, S.(2);
(1)Hull York Medical School, Department of Gastroenterology, Hull, United Kingdom;(2)Hull University Teaching Hospitals, IBD Unit- Department of Gastroenterology, Hull, United Kingdom;
P375: Faecal calprotectin variation after induction therapy with infliximab to predict clinical, endoscopic and ultrasonographic remission in Crohn’s disease patientsECCO'22Year: 2022
Authors: Revés, J.(1);Morão, B.(1);Gomes, C.F.(1);Nascimento, C.(1);Abreu, N.(2);Gonçalves, T.C.(3);Castro, F.(3);Freitas, M.(3);Moreira, M.J.(3);Cotter, J.(3);Pereira, F.(4);Caldeira, A.(4);Sousa, R.(4);Coelho, R.(5);Macedo, G.(5);Macedo, C.(6);Ferreira, M.(6);Glória, L.(1);Torres, J.(1);Palmela, C.(1);
(1)Hospital Beatriz Ângelo, Gastrenterology Department, Loures, Portugal;(2)Hospital Dr. Nélio Mendonça, Gastrenterology Department, Funchal, Portugal;(3)Hospital da Senhora da Oliveira- Life and Health Sciences Research Institute- School of Medicine- University of Minho- Braga- ICVS/3B’s- PT Government Associate Laboratory, Gastrenterology Department, Guimarães/Braga, Portugal;(4)Unidade Local de Saúde de Castelo Branco- EPE- Hospital Amato Lusitano, Gastrenterology Department, Castelo Branco, Portugal;(5)Centro Hospitalar de São João- Porto, Gastrenterology Department, Porto, Portugal;(6)Centro Hospitalar Universitário de Coimbra, Gastrenterology Department, Coimbra, Portugal;
P376: Switching from intravenous to subcutaneous vedolizumab maintenance treatment; feasibility, safety and clinical outcomeECCO'22Year: 2022
Authors: Wiken, T.(1,2);Høivik, M.L.(1,2);Buer, L.(1);Bolstad, N.(3);Moum, B.A.(1,2);Medhus, A.W.(1);
(1)Oslo University Hospital, Departement of Gastroenterology, Oslo, Norway;(2)University of Oslo, Institute of Clinical Medicine, Oslo, Norway;(3)Oslo University Hospital, Departement of Medical Biochemistry, Oslo, Norway;
P377: Impact of moderate-to-severe endoscopic disease criteria on endoscopic response, endoscopic remission, and deep remission in patients receiving ustekinumab or adalimumab in the SEAVUE studyECCO'22Year: 2022
Authors: Allez, M.(1);Lewis, J.D.(2);Hanauer, S.B.(3);Danese, S.(4);Irving, P.M.(5,6);Gasink, C.(7);Hoops, T.(8);Izanec, J.L.(7);Ma, T.(7);Loftus- Jr., E.V.(9);Scherl, E.J.(10);Panaccione, R.(11);Sandborn, W.J.(12);Sands, B.E.(13);
(1)Hôpital Saint-Louis- Assistance Publique-Hôpitaux de Paris AP-HP- INSERM U1160 and Université de Paris, Gastroenterology Department, Paris, France;(2)Perelman School of Medicine at the University of Pennsylvania, Division of Gastroenterology, Philadelphia, United States;(3)Northwestern University Feinberg School of Medicine, Department of Gastroenterology, Chicago, United States;(4)IRCCS Ospedale San Raffaele and Università Vita-Salute San Raffaele, Gastroenterology and Endoscopy, Milan, Italy;(5)Guy’s and Saint Thomas’ Hospitals NHS Trust, Department of Gastroenterology, London, United Kingdom;(6)King’s College London, School of Immunology and Microbial Sciences, London, United Kingdom;(7)Janssen Scientific Affairs- LLC, Immunology, Horsham, United States;(8)Janssen Pharmaceutical Companies of Johnson & Johnson, Immunology Global Medical Affairs, Horsham, United States;(9)Mayo Clinic College of Medicine, Division of Gastroenterology and Hepatology, Rochester, United States;(10)New York Presbyterian Hospital Weill Cornell Medicine, Weill Department of Medicine, New York, United States;(11)University of Calgary, Inflammatory Bowel Disease Unit- Division of Gastroenterology and Hepatology, Calgary, Canada;(12)University of California San Diego, Division of Gastroenterology, La Jolla, United States;(13)Icahn School of Medicine at Mount Sinai, Dr. Henry D. Janowitz Division of Gastroenterology, New York, United States;
P378: Rectal bleeding and stool frequency improvement with tofacitinib dose escalation to 10 mg BID in patients with Ulcerative Colitis following loss of response on tofacitinib 5 mg BID maintenance therapy: Results from OCTAVE OpenECCO'22Year: 2022
Authors: Allegretti, J.R.(1);Gecse, K.B.(2);Chiorean, M.V.(3);Argollo, M.(4);Guo, X.(5);Lawendy, N.(5);Su, C.(5);Mundayat, R.(6);Paulissen, J.(6);Salese, L.(5);Irving, P.M.(7);
(1)Brigham and Women's Hospital, Division of Gastroenterology- Hepatology and Endoscopy, Boston- MA, United States;(2)Amsterdam University Medical Center, Department of Gastroenterology and Hepatology, Amsterdam, The Netherlands;(3)-, Swedish Medical Center, Seattle- WA, United States;(4)Federal University of São Paulo, Department of Gastroenterology, São Paulo, Brazil;(5)-, Pfizer Inc, Collegeville- PA, United States;(6)-, Pfizer Inc, New York- NY, United States;(7)Guy’s and St Thomas’ Hospital, IBD Unit, London, United Kingdom;
P379: Trends in Colectomy Rates and Biologic use over a 30-year period: What has changed?ECCO'22Year: 2022
Authors: Doherty, J.(1);Stack, R.(1);Fennessy, A.(1);Cullen, G.(1);Mulcahy, H.(1);Sheridan, J.(1);Kevans, D.(1);Doherty, G.(1);
(1)Centre for Colorectal Disease- St Vincent’s University Hospital & School of Medicine- University College Dublin, Gastroenterology, Dublin, Ireland;
P380: Early improvement of endoscopic outcomes with risankizumab is associated with reduced hospitalisation and surgery rates in patients with Crohn’s diseaseECCO'22Year: 2022
Authors: Feagan, B.G.(1);Colombel, J.F.(2);Panaccione, R.(3);Schreiber, S.(4);Ferrante, M.(5);Kamikozuru, K.(6);Lee, W.J.(7);Griffith, J.(7);Kligys, K.(7);Kalabic, J.(8);Chen, N.(7);Dubinsky, M.(2);
(1)Western University- Alimentiv Inc., n/a, London, Canada;(2)Icahn School of Medicine at Mt. Sinai, n/a, New York, United States;(3)University of Calgary, n/a, Calgary, Canada;(4)University Hospital Schleswig-Holstein, n/a, Kiel, Germany;(5)University Hospital Leuven, n/a, Leuven, Belgium;(6)Hyogo College of Medicine, n/a, Nishinomiya, Japan;(7)AbbVie Inc., n/a, North Chicago, United States;(8)AbbVie Deutschland GmbH & Co. KG, n/a, Ludwigshafen, Germany;
P381: Factors predicting risk of colectomy in patients receiving first line steroid and second line biologic salvage therapy for Acute Severe Ulcerative ColitisECCO'22Year: 2022
Authors: Skinezes, Y.(1,2);Meir, Z.Y.(1,2);Abitbol, C.M.(1,2);Levartovsky, A.(1,2);Klang, E.(1,2);Kopylov, U.(1,2);Ben-Horin, S.(1,2);Ungar, B.(1,2);
(1)Sheba medical center- Tel Hashomer, Gastroenterology, Ramat Gan, Israel;(2)Tel Aviv University, Sackler School of Medicine, Tel Aviv, Israel;
P383: Ustekinumab as an opportunity for refractory Ulcerative Colitis patients.ECCO'22Year: 2022
Authors: Iborra, M.(1);Soutullo, C.(1);Gimeno, M.(1);Bastida, G.(1);Aguas, M.(1);Cerrillo, E.(1);Sáez-González, E.(1);Garrido, A.(1);Mínguez, A.(1);Bordetas, J.(1);Nos, P.(1);
(1)Hospital Universitario y Politécnico La Fe, Gastroenterology Department, Valencia, Spain;
P384: Postoperative Endoscopic Recurrence In Patients With Crohn’s Disease After “Curative” Ileocecal Resection on Prophylaxis Treatment With Either Anti-TNFs, Vedolizumab or Ustekinumab: A Real-World Multicentre European StudyECCO'22Year: 2022
Authors: Yanai, H.(1,2);Amir Barak , H.(1,2);Kagramanova, A.(3);Knyazev , O.(3);Sabino, J.(4);Haenen, S.(4);Mantzaris , G.J.(5);Mountaki, K.(5);Pugliese, D.(6);Armuzzi, A.(6,7);Furfaro, F.(8);Fiorino, G.(8);Drobne, D.(9,10);Kurent, T.(10);Yassin, S.(2,11);Maharshak, N.(2,11);Castiglione, F.(12);Nardone, O.M.(12);de Sire, R.(12);Farkas, K.(13);Molnar, T.(13);Krznaric, Z.(14);Brinar, M.(14);Chashkova, E.(15);Margolin, M.L.(2,16);Kopylov, U.(2,16);Bezzio, C.(17);Bar-Gil Shitrit, A.(18);Lukas , M.(19,20);Chaparro, M.(21);Truyens, M.(22,23);Nancey, S.(24);Revés, J.(25);Avni-Biron, I.(1,2);Ollech, J.E.(1,2);Dotan, I.(1,2);Aharoni Golan, M.(1,2);
(1)Rabin Medical Center, Division of Gastroenterology, Petah Tikva, Israel;(2)Tel Aviv University, Sackler Faculty of Medicine, Tel Aviv, Israel;(3)Moscow Clinical Scientific Centre n.a. A.S. Loginov, IBD department, Moscow, Russian Federation;(4)University Hospitals Leuven, Department of Gastroenterology, Leuven, Belgium;(5)GHA 'Eveggelismos-Polykliniki', Department of Gastroenterology, Athens, Greece;(6)Fondazione Policlinico Universitario @A. Gemelli@ IRCCS, CEMAD- Inflammatory Bowel Disease Unit- Unità Operativa Complessa di Medicina Interna e Gastroenterologia- Dipartimento di Scienze Mediche e Chirurgiche, Rome, Italy;(7)Università Cattolica del Sacro Cuore, Dipartimento Universitario di Medicina e Chirurgia Traslazionale, Rome, Italy;(8)Humanitas Clinical and Research Center – IRCCS, IBD Unit- Rozzano, Milan, Italy;(9)University Medical Centre Ljubljana, Department of Gastroenterology, Ljubljana, Slovenia;(10)University of Ljubljana, Medical Faculty, Ljubljana, Slovenia;(11)Tel Aviv Medical Center, Department of Gastroenterology and Liver Diseases, Tel Aviv, Israel;(12)University of Naples Federico II, Department of Clinical Medicine and Surgery, Naples, Italy;(13)University of Szeged, Department of Medicine, Szeged, Hungary;(14)University Hospital Centre, Department of Gastroenterology- Hepatology and Nutrition, Zagreb, Croatia;(15)Irkutsk Scientific Center of Surgery and Traumatology, Department of Reconstructive Surgery, Irkutsk, Russian Federation;(16)Sheba medical center, Gastroenterology department, Tel Hashomer, Israel;(17)Rho Hospital, Gastroenterology Unit- Asst Rhodense, Milano, Italy;(18)Shaare Zedek Medical Center, Digestive Diseases Institute, Jerusalem, Israel;(19)ISCARE Clinical Centre, Clinical and Research Centre for Inflammatory Bowel Disease, Prague, Czech Republic;(20)General University Hospital and First Faculty of Medicine- Charles University, Institute of Medical Biochemistry and Laboratory Medicine, Prague, Czech Republic;(21)Hospital Universitario de La Princesa- Instituto de Investigación Sanitaria Princesa IIS-IP- Universidad Autónoma de Madrid and Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas CIBERehd, Gastroenterology Department, Madrid, Spain;(22)University Hospital Ghent, IBD unit-Department of Gastroenterology, Ghent, Belgium;(23)Ghent University, Department of Internal Medicine and Pediatrics, Ghent, Belgium;(24)Lyon-Sud hospital- Hospices Civils de Lyon, Department of Gastroenterology, Lyon, France;(25)Hospital Beatriz Ângelo- Loures, Gastroenterology Division, Lisbon, Portugal;
P385: Tailoring induction treatment for children with Crohn’s disease.ECCO'22Year: 2022
Authors: Cuomo, M.(1);Carobbio, A.(2);Aloi , M.(3);Alvisi , P.(4);Banzato, C.(5);Bosa, L.(6);Bramuzzo, M.(7);Campanozzi, A.(8);Catassi , G.(3);D'Antiga, L.(2);Di Paola, M.(9);Felici, E.(10);Fioretti , M.T.(11);Gatti , S.(12);Graziano, F.(13);Lega , S.(7);Lionetti , P.(9);Marseglia , A.(14);Martinelli , M.(11);Musto, F.(15);Sansotta, N.(2);Scarallo , L.(9);Zuin, G.(15);Norsa, L.(16);
(1)San Carlo Hospital - ASST Santi Paolo e Carlo, Department of Paediatric, Milano, Italy;(2)ASST Papa Giovanni XXIII, FROM Research foundation, Bergamo, Italy;(3)Sapienza University of Rome, Paediatric Gastroenterology and Liver Unit- Department of Maternal and Child Health, Roma, Italy;(4)Maggiore Hospital, Paediatric Gastroenterology Unit, Bologna, Italy;(5)University of Verona, Paediatric Clinic- Department of Surgical Sciences- Dentistry- Gynaecology and Paediatrics- Paediatric Division, Verona, Italy;(6)University of Padova, Department of Women’s and Children’s Health, Padova, Italy;(7)Institute for Maternal and Child Health @IRCCS Burlo Garofolo@, Paediatric Gastroenterology, Trieste, Italy;(8)University of Foggia, Pediatrics- Department of Medical and Surgical Sciences, Foggia, Italy;(9)University of Florence, Gastroenterology and Nutrition Unit- Meyer children’s Hospital- Department Neurofarba-, Florence, Italy;(10)Children Hospital- AO SS Antonio e Biagio e C. Arrigo, Pediatric and Paediatric Emergency Unit- “U. Bosio” Centre for Paediatric Digestive Diseases, Alessandria, Italy;(11)University of Naples “Federico II”, Department of Translational Medical Science- Section of Paediatrics, Napoli, Italy;(12)Polytechnic University of Marche- G. Salesi Children's Hospital, Department of Paediatrics, Ancona, Italy;(13)Villa Sofia Cervello Hospital-, Pediatric Unit, Palermo, Italy;(14)“IRCCS Casa Sollievo della Sofferenza”, Division of Paediatrics, San Giovanni Rotondo, Italy;(15)University of Milano Bicocca- Fondazione MBBM- Onlus San Gerardo Hospital, Paediatric Department, Monza, Italy;(16)Ospedale Papa Giovanni, Paediatric Hepatology Gastroenterology and Transplantation, Mlano, Italy;
P386: Predictive models for assessing the response to ustekinumab in Crohn’s disease patientsECCO'22Year: 2022
Authors: Hubert, A.(1);Bottieau, J.(1);Toubeau, J.F.(1);Franchimont, D.(2,3);Vallée, F.(1);Liefferinckx, C.(2,3);
(1)University of Mons, Department of Electrical Engineering, Mons, Belgium;(2)Hôpital Erasme, Department of Gastroenterology, Brussels, Belgium;(3)Université libre de Bruxelles, Laboratory of experimental gastroenterology, Brussels, Belgium;
P387: Rapid Implementation of an Evidence-Based, Virtual COVID-19 Vaccine Education Clinic at the Nova Scotia Collaborative Inflammatory Bowel Disease Clinic (NSCIBD) ProgramECCO'22Year: 2022
Authors: Komeylian, H.(1);Stewart, M.(1);Currie, B.(2);Phalen-Kelly, K.(2);Heisler, C.G.(2);Jones, J.(1);
(1)Dalhousie University, Medicine- Gastroenterology, Halifax, Canada;(2)Nova Scotia Health, Division of Digestive Care & Endoscopy, Halifax, Canada;
